The Trend and Endgame of AI + Healthcare (Part 2)

WealthCoffee · 2026-04-07T02:43:06+00:00

This week, Hong Kong medical stocks were tested by macro news and fundamentals, with most prices fluctuating downward, but Jinxin Reproductive rose against the trend due to its shareholder return plan. Overall trading volume was close to last week, with sluggish performance expectations, requiring long-term trust to be established.

WealthCoffee

2026-04-07 02:43:06

Abstract generation in progress

This year’s 13th trading week (20260323-20260329), Hong Kong healthcare stocks this week were hit not only by shocks from macro news, but also by the annual “fundamentals” test. Although annual reports will be released in the coming week, well-informed institutions are sure to take action this week. It’s expected that most results will not meet expectations, so in fact trading volumes this week are about the same as last week, and most share prices have been fluctuating downward. But KinSun Reproductive is a bright spot: on Thursday it released an “Shareholder Return Plan” that is quite innovative. This information-rich announcement drove a volume surge and upside breakout on the day, and then on Friday the upward trend continued as well, with KinSun closing every day in the red throughout this week. Good ideas are certainly good, but only what can truly be implemented can build the long-term credibility of healthcare stocks. Once that is broken again, the outcome at that time won’t be something a single healthcare stock can carry.

We recommend entering the Caixin database, where you can look up macroeconomics, stocks and bonds, and company profiles at any time—financial and economic data are all at your fingertips.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes